Thomas James Doyle Sells 4,949 Shares of Kura Oncology, Inc. (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURA) SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Kura Oncology Trading Down 1.0 %

Shares of NASDAQ KURA opened at $7.69 on Thursday. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a one year low of $6.98 and a one year high of $24.17. The business has a 50-day moving average price of $9.06 and a two-hundred day moving average price of $15.63. The firm has a market capitalization of $598.01 million, a PE ratio of -3.26 and a beta of 0.81.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.01. During the same quarter in the previous year, the company earned ($0.50) EPS. As a group, analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on KURA. TD Cowen restated a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. Jefferies Financial Group reduced their target price on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a report on Thursday, November 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a report on Monday, December 9th. Scotiabank reduced their price objective on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th. Finally, HC Wainwright boosted their target price on Kura Oncology from $32.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, November 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $27.38.

Hedge Funds Weigh In On Kura Oncology

Hedge funds have recently modified their holdings of the stock. nVerses Capital LLC acquired a new stake in Kura Oncology during the third quarter valued at $25,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Kura Oncology by 11.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock valued at $144,000 after buying an additional 1,750 shares during the last quarter. Point72 DIFC Ltd bought a new stake in shares of Kura Oncology in the 3rd quarter valued at approximately $146,000. Quarry LP acquired a new position in Kura Oncology in the second quarter worth approximately $196,000. Finally, Erste Asset Management GmbH bought a new position in Kura Oncology during the third quarter valued at approximately $215,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.